関節リウマチにおける第一選択薬としてトファシチニブとメトトレキサートの比較: オープンラベル無作為化試験
Int J Rheum Dis. 2023;26(9):1729–1736 doi: 10.1111/1756-185X.14801
This single-centre study by Khan, et al. suggests that high-dose methotrexate (25 mg/week, subcutaneously) may be as efficacious as tofacitinib in patients with established RA who are DMARD naïve or have not received a therapeutic dose of DMARDs.
In this this open-label, randomised, controlled, parallel-group, 3-month trial, Khan et al. compared tofacitinib 10 mg and MTX as first-line DMARDs for RA.
Keywords:
